Literature DB >> 1672623

Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors.

S M Redmond1, F Joncourt, K Buser, A Ziemiecki, H J Altermatt, M Fey, G Margison, T Cerny.   

Abstract

Drug resistance is a major problem in cancer chemotherapy. Treatment protocols generally include a number of different cytotoxic drugs given in combination. Therefore, drug resistance in the tumor is likely to result from the coexpression of several cellular activities able to prevent cell killing by any of the drugs used. In this study we have measured several potential drug resistance mechanisms consisting of the multidrug resistance gene product P-glycoprotein, glutathione, glutathione-transferase and -peroxidase, and the DNA repair enzyme O6-alkylguanine-DNA-alkyltransferase in samples of colon carcinoma and normal adjacent mucosa from 23 untreated patients. All of these, with the exception of P-glycoprotein, showed significant increases in tumor tissue levels when compared with normal tissue from the same patient. The significance was highest for glutathione peroxidase (P less than or equal to 0.0005). Individual patients, however, showed very different patterns, with none, several, or all monitored resistance mechanisms elevated in the tumor. The implications both in the choice of drugs and in the use of resistance modifying agents to improve therapy for the individual patient are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672623

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Sensitization of human colon tumour cell lines to carmustine by depletion of O6-alkylguanine-DNA alkyltransferase.

Authors:  A Magull-Seltenreich; W J Zeller
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

2.  Wip1 gene silencing enhances the chemosensitivity of human colon cancer cells.

Authors:  Zhong-Sheng Xia; Di Wu; Wa Zhong; Xi-Ji Lu; Tao Yu; Qi-Kui Chen
Journal:  Oncol Lett       Date:  2017-06-09       Impact factor: 2.967

Review 3.  Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.

Authors:  D J Stewart; G P Raaphorst; J Yau; A R Beaubien
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 4.  Glutathione levels in human tumors.

Authors:  Michael P Gamcsik; Mohit S Kasibhatla; Stephanie D Teeter; O Michael Colvin
Journal:  Biomarkers       Date:  2012-08-20       Impact factor: 2.658

5.  Flow cytometric analysis of multidrug-resistance-associated antigen (P-glycoprotein) and DNA ploidy in human colon cancer.

Authors:  M Danova; M Giordano; E Erba; S Palmeri; V Candiloro; A Riccardi; G Ucci; G Mazzini; M D'Incalci; E Ascari
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 6.  Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?

Authors:  F Gieseler; P Rudolph; G Kloeppel; U R Foelsch
Journal:  Int J Colorectal Dis       Date:  2003-05-28       Impact factor: 2.571

Review 7.  Modulation of tumor cell response to chemotherapy by the organ environment.

Authors:  I J Fidler; C Wilmanns; A Staroselsky; R Radinsky; Z Dong; D Fan
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

Review 8.  Clinical significance of cellular resistance in tumours to cytotoxic chemotherapy and radiotherapy.

Authors:  M Pomeroy; M Moriarty
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 9.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 10.  Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases.

Authors:  Asima Bhattacharyya; Ranajoy Chattopadhyay; Sankar Mitra; Sheila E Crowe
Journal:  Physiol Rev       Date:  2014-04       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.